Back
Speaker illustration

Mrs Oksana Obertynska

National Pirogov Memorial Medical University, Vinnitsa (Ukraine)

Obertynska Oksana was taking a postgraduate course at the department of cardiology. In 2007 she maintained the masters thesis in profession line -cardiology. She was working as cardiologist at the Military Hospital from 2001 till 20013. She has been working at department of propedeutics internal diseases of Vinnitsa Medical University from 2010 has been treating patients in the cardiology section. She delivers lectures and carries out practical studies with the third-year students of Medical faculty as well as with foreign students, carries out seminars with doctor-interns. She is an author of 18 scientific articles. Field of interests: cardiology, imaging, digital medicine.

Presentations Articles

The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Understanding the effects and utilisation of SGLT2 inhibitors in heart failure

Access
Like
Thumbnail

Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

Access
Like
Thumbnail

The efficiency of dapagliflozin as add-on therapy in obese patients with resistant hypertension and chronic kidney disease

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacotherapy

Session: Hypertension e-posters

Access
Like
Thumbnail

Weight loss therapy in obese hypertensive patients: the effect of orlistat versus metformin

Event: ESC Congress 2021 - The Digital Experience

Topic: Obesity

Session: Risk Factors and Prevention ePosters

Access
Like
Thumbnail

The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacotherapy

Session: Chronic heart failure e-posters

Access
Like
Thumbnail

The efficacy and safety of mineralocorticoid-receptor antagonists: spironolactone and eplerenone in resistant hypertension and chronic kidney disease stages 3

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Hypertension treatment: drugs and devices

Access
Like
Thumbnail

The relationship between plasma renin and aldosterone levels and the reduction of blood pressure with spironolactone in patients with resistant hypertension.

Event: ESC Congress 2019

Topic: Renin-Angiotensin System

Session: Secondary hypertension and genes

Access
Like
Thumbnail

The renin and aldosterone levels at resistant hypertension and its connection with other clinical features

Event: ESC Congress 2018

Topic: Renin-Angiotensin System

Session: Hyperaldosteronism and hypertension: look harder!

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources